Silicon Investor - Under $0.01 (..subpenny..) stocks

[Benny-Rubin] MBAK Energy Solutions, Inc. (OTC:MBAK) begins delivery to Indian Customers – par...

Benny-Rubin — 12/10/2025 11:08:28 AM

MBAK Energy Solutions, Inc. (OTC:MBAK) begins delivery to Indian Customers – part of $65 Million in 2026 Order fulfillmentSEOUL, South Korea and SHENZHEN, China and WILMINGTON, N.C., Dec. 10, 2025 (GLOBE NEWSWIRE) -- MBAK Energy Solutions, Inc. (OTC:MBAK) has begun delivering on the $65,000,000 USD in production orders booked for 2026. Deliveries include against the BESS order for the Indian power grid, delivery of electric two and three-wheeler personal transports, and battery cells for data center power facilities. The BESS contract directly supports Indian efforts to increase national energy production capacity through renewable sources of electricity generation and storage. The company continues to field enquiries from power providers and commercial users across the region, and into North America.

Demand for the company’s mobility products, specifically electric two wheelers for Europe, India, and Africa remains strong due to the company’s record of innovation, reliability, safety and quality.

MBAK Energy Solutions, Inc. is engaged in the development, manufacturing, and commercialization of non-fossil fuel energy products. The company has expertise in the design and production of lithium, sodium, and solid-state batteries for industrial, medical, portable electronics, and EV applications.

Contact: info@mbakcorp.com, press@mbakcorp.com

Website: www.mbakcorp.com

[Benny-Rubin] $ADHC from 0012 to 0035 on Friday. Excellent volume and major PR to come on Wedn...

Benny-Rubin — 5/26/2025 7:31:46 AM

$ADHC from 0012 to 0035 on Friday. Excellent volume and major PR to come on Wednesday! :)

[Benny-Rubin] Gary,ADHC is gonna have big news Monday. :)

Benny-Rubin — 5/17/2025 9:46:08 PM

[Benny-Rubin] Gary, I devoted my career in the OTC and I had to switch gears into the NASDAQ m...

Benny-Rubin — 4/22/2024 11:00:04 AM

Gary, I devoted my career in the OTC and I had to switch gears into the NASDAQ micro Cap sector. Why the OTC dropped dead is beyond me and its very sad.

NWBO is a nice biotech,I never bought in but have known it for years. I love bio tech and am in several on the NASDAQ. CCCC is my favorate one and has a habbit of taking 100% runs but just to be shorted down. My target of $10 was not only hit but surpassed to $12 This baby began at $2 late last year and I scored twice with her. They are in bed with MERC and the stock is in an area under $7.00 so the shorts should begin a cover soon as News is due. We shall see.

[Gary Mohilner] Thanks Benny, On first glance HYSR looks interesting, the question in my mind ...

Gary Mohilner — 4/20/2024 6:38:45 PM

Thanks Benny,

On first glance HYSR looks interesting, the question in my mind however is whether the hydrogen can provide more power than the electricity generated by solar alone. I'll take a bigger look at it later.

My far bigger investment is NWBO, which just dipped below $.50. It's in roughly the last 30 days of the UK evaluation of it's vaccine for brain cancer. I believe an approval will bring at least $2, and that will be just the beginning.

CRTG is really a mystery since no one knows how much Core Optics, who essentially is taking over the company in buying the corporate shell, is bringing to the table, they will take over the management and while the development of better battery media will continue to advance, Core Optics has a building market for what it's already making in Korea, and looking to break into the US market as well as becoming a listed stock, and wanting to move to the Nasdaq. Much should be revealed once the merger completes and new quarterlies are available for the merged companies. I do believe it will be worth more than it's selling for today.

Gary

[Benny-Rubin] Yea I look but the pinks have been dead since Nov 2021,maybe a bounce here and t...

Benny-Rubin — 4/20/2024 1:16:53 PM

Yea I look but the pinks have been dead since Nov 2021,maybe a bounce here and there. I know EPAZ and I think its way too low but who knows. CRTG is on the OTCQB so an entire different story. I like what they do but it needs awareness. The only OTCQB I currently own is HYSR which is a little above 01.

[Gary Mohilner] Anyone still looking at sub-penny stocks. If so, have a look at EPAZ, just abov...

Gary Mohilner — 4/18/2024 4:29:10 PM

Anyone still looking at sub-penny stocks. If so, have a look at EPAZ, just above a penny, CRTG. Both are working with drones, battery technology, etc. CRTG is merging with Core Optics, who'll own 80% but will be bringing real revenue into the company. Both have interesting and potentially explosive technologies.

Gary

[Benny-Rubin] TSOI up 62% today

Benny-Rubin — 4/19/2023 10:38:00 PM

[Benny-Rubin] Talk about getting in early. TSOI gonna run hard again. Currently 0047.

Benny-Rubin — 2/28/2023 3:08:38 PM

[Esoteric1] $ETEK has it even done it’s thing yet? Must be nice to be in early like this one...

Esoteric1 — 2/7/2022 1:38:39 PM

$ETEK has it even done it’s thing yet? Must be nice to be in early like this one

stocktwits.com

[Esoteric1] Good information here. If there’s an NDA we can’t know the new company yet but ...

Esoteric1 — 1/26/2022 11:28:37 AM

Good information here.

If there’s an NDA we can’t know the new company yet but at least some really good general info is being released.

twitter.com

twitter.com

twitter.com

twitter.com

Micro loans?

When the incoming entity takes control we will know.

[Esoteric1] Possible? Yeah I’d say some of this stuff is possible bizjournals.com This on...

Esoteric1 — 1/25/2022 9:10:54 AM

Possible? Yeah I’d say some of this stuff is possible

bizjournals.com

This one according to his profile was made a millionaire with DPLS and likes ETEK…

stocktwits.com

Use or lose

[Esoteric1] Apologies if this is the wrong board. I searched and there is truly nothing like...

Esoteric1 — 1/23/2022 5:11:34 PM

Apologies if this is the wrong board. I searched and there is truly nothing like it.
Emergent has a good Q & A on the nuances between a reverse merger and a SPAC

ETEK is not a Spac

HALL OF FAME SHELL and REVERSE MERGER RUNS:

LFZA(USSE) - ran from .0002 to .84 (420,000%) - investorshub.com
SXML(AMRP) - ran from 0.03 to $50 (160,000%) - investorshub.com
CYBR - ran from 0.001 to 0.50 ( 50,000%) - investorshub.com
DEXTQ - ran from 0.0005 to 0.21 ( 42,000%) - investorshub.com
CKXE(SPEA) - ran from .10 to 30.60 ( 31,000%) - investorshub.com
OBDP(VQPI) - ran from 0.006 to 1.50 ( 25,000%) - investorshub.com
PKTO(USAC) - ran from 0.0002 to 0.049( 25,000%) - investorshub.com
FCNK - ran from .02 to 3.50 ( 17,000%) - investorshub.com
VIPM - ran from 0.0001 to 0.015 ( 15,000%) - investorshub.com
SLJB(LFWK) - ran from 0.0015 to 0.20 ( 13,000%)
NXCN(CYKE) - ran from 0.01 to 1.30 ( 13,000%) - investorshub.com
HCOM - ran from 0.001 to 0.10 ( 9,900%) - investorshub.com
VLNT - ran from 0.0001 to 0.009 ( 8,900%) - investorshub.com
CSHD(FHAL) - ran from .05 to 4.00 ( 8,000%)
PRRY(ABDL) - ran from .02 to 1.60 ( 7,900%) - investorshub.com
IFLI(PGNT) - ran from .3 to 17.00 ( 6,000%) - investorshub.com
LRSY - ran from 0.025 to 1.50 ( 5,900%) - investorshub.com
PLSO - ran from .0005 to 0.03 ( 5,900%) - investorshub.com
TMXU - ran from .0007 to 0.04 ( 5,600%)
CFUL(CNDO) - ran from .073 to $4.19 ( 5,600%) - investorshub.com
GWRX - ran from 0.01 to 0.475 ( 4,700%) - investorshub.com
UMCC - ran from 0.003 to 0.14 ( 4,600%)
MXDY(2003) - ran from 0.01 to 0.42 ( 4,100%)
RBID - ran from 0.001 to 0.04 ( 3,900%)
BUIG - ran from 0.0015 to 0.05 ( 3,200%) - investorshub.com
DLGIE(TOCK) - ran from 0.011 to 0.35 ( 3,100%) - investorshub.com
PGNF - ran from 0.002 to 0.065 ( 3,100%)
FCRZ - ran from 0.003 to 0.095 ( 3,100%)
WPRO - ran from 0.003 to 0.085 ( 2,700%)
DGIF(TDRPQ) - ran from 0.06 to 1.70 ( 2,700%) - investorshub.com
RTGV - ran from 0.005 to 0.12 ( 2,300%) - investorshub.com
BUNZQ - ran from 0.005 to 0.12 ( 2,300%)
NVBF(NVAO) - ran from 0.25 to 6.00 ( 2,300%)
NNRF(SFDE) - ran from 0.003 to 0.07 ( 2,200%) - investorshub.com
FCCN - ran from 0.003 to 0.065 ( 2,100%)
SSTP - ran from 0.017 to 0.38 ( 2,100%) - investorshub.com
LNBO - ran from 0.005 to 0.09 ( 1,700%) - investorshub.com
MNEI - ran from 0.001 to 0.017 ( 1,600%)
CSBR - ran from 0.05 to 0.80 ( 1,500%) - investorshub.com
TVCE - ran from 0.0002 to 0.0028 ( 1,300%)
IOGH - ran from 0.015 to 0.20 ( 1,300%)
PPXP(SFPH) - ran from 0.70 to 10.00 ( 1,300%) - investorshub.com
RGNO(FCNK) - ran from 0.02 to 0.25 ( 1,200%)
EPMO - ran from 0.008 to 0.10 ( 1,200%)
OCRI - ran from 0.001 to 0.013 ( 1,200%)
ATGR(ATEG) - ran from 0.004 to 0.058 ( 1,200%) - investorshub.com
VIVI(AXGI) - ran from 0.002 to 0.028 ( 1,100%)
SCYA - ran from 0.001 to 0.011 ( 1,000%)
DPDW(MQPH) - ran from .10 to.85 ( 800%)
PRPM(JLNY) - ran from .01-.08 ( 700%)
TLBT(TCHL) - ran from 0.015 to 0.12 ( 700%)
PASW - ran from 0.30-2.00 ( 600%) - investorshub.com
COBN - ran from 0.007 to 0.04 ( 500%)

investorshub.advfn.com

Use or lose

[Esoteric1] Metal Arts Company, Inc. – Anatomy Of A Corporate Shell/Reverse Merger Trade – I...

Esoteric1 — 1/23/2022 12:08:51 PM

Metal Arts Company, Inc. – Anatomy Of A Corporate Shell/Reverse Merger Trade – In

Progresshttps://seekingalpha.com/instablog/3646631-anthony-cataldo/5664588-metal-arts-company-inc-anatomy-of-corporate-shell-reverse-merger-trade-in-progress

seekingalpha.com

[Esoteric1] $ETEK Look into this. If you don’t make money….. don’t blame me… mobile.twitter...

Esoteric1 — 1/23/2022 12:08:05 PM

$ETEK Look into this. If you don’t make money….. don’t blame me…

mobile.twitter.com

stocktwits.com

mobile.twitter.com

investorshub.advfn.com

[Benny-Rubin] TSOI up 135% today. Impressive

Benny-Rubin — 12/29/2021 1:08:03 AM

[Benny-Rubin] TSOI, this one is for you. There will be a gargantuan short squeeze within 2 wee...

Benny-Rubin — 12/23/2021 12:44:25 AM

TSOI, this one is for you. There will be a gargantuan short squeeze within 2 weeks. You need to read my posts from last year and early this year. Shares were sub penny and shot up to .17 very quickly.
Will REPEAT. Huge buy in this 02 area,
Regards

Benny

[WoodEric0] $MSPC - MetroSpaces - It might be surprising to discover that the price of Metro...

WoodEric0 — 12/17/2021 12:21:25 PM

$MSPC - MetroSpaces - It might be surprising to discover that the price of MetroSpaces, A Cutting-Edge Real Estate Tech Company, isn’t as high as you’d expect it to be right now – which means now is a great time to get in on the ground up and hold stocks while this promising company grows.

ritzherald.com

[Esoteric1] $RGBP Use or Lose investorshub.advfn.com

Esoteric1 — 12/16/2021 10:17:00 PM

[Esoteric1] $RGBP investorshub.advfn.com Use or lose

Esoteric1 — 11/26/2021 1:26:30 PM

[Esoteric1] $RGBP microcapdaily.com

Esoteric1 — 11/21/2021 1:13:51 AM

[Esoteric1] $RGBP twitter.com

Esoteric1 — 11/18/2021 6:32:28 AM

[Esoteric1] $RGBP newsfilter.io

Esoteric1 — 11/17/2021 6:06:50 PM

[Esoteric1] $RGBP $$$ New cancer treatments may be on the horizon—thanks to mRNA vaccines ...

Esoteric1 — 11/14/2021 3:08:42 PM

$RGBP $$$
New cancer treatments may be on the horizon—thanks to mRNA vaccines
The COVID-19 pandemic brought mRNA vaccines into the limelight. But the technology may also prove to be a powerful weapon against hard-to-treat cancers.

BYSTACEY COLINO
PUBLISHED JULY 8, 2021
• 12 MIN READ

Molly Cassidy was studying for the Arizona bar exam in February 2019 when she felt an excruciating pain in her ear. The pain eventually radiated down through her jaw, leading her to discover a bump under her tongue. “I had several doctors tell me it was stress-related because I was studying for the bar and I had a 10-month-old son,” recalls Cassidy, who also has a Ph.D. in education. After continuing to seek medical care, she found out that she had an aggressive form of head and neck cancer that required intensive treatment.

After doctors removed part of her tongue along with 35 lymph nodes, Cassidy went through 35 sessions of radiation concurrent with three cycles of chemotherapy. Ten days after she completed treatment, Cassidy noticed a marble-like lump on her collarbone. The cancer had returned—and with a vengeance: It had spread throughout her neck and to her lungs. “By that point, I was really out of options because the other treatments hadn’t worked,” says Cassidy, now 38, who lives in Tucson. “In the summer of 2019, I was told my cancer was very severe and to get my affairs in order. I even planned my funeral.”

When doctors removed the tumor from her collarbone, they told her that she might be eligible to join a clinical trial at the University of Arizona Cancer Center that was testing an mRNA (messenger ribonucleic acid) vaccine—similar technology to the Pfizer and Moderna COVID-19 vaccines—in combination with an immunotherapy drug to treat colorectal and head and neck cancers. Whereas the COVID-19 vaccines are preventative, mRNA vaccines for cancer are therapeutic, and Cassidy jumped at the opportunity to participate. “I was at the right place at the right time for this clinical trial,” she says.

Back when people first heard about Pfizer-BioNTech and Moderna’s COVID-19 vaccines, the mRNA technology behind them sounded like the stuff of science fiction. But while the mRNA approach seems revolutionary, long before anyone had heard of COVID-19, researchers had been developing mRNA vaccines to fight cancer, autoimmune diseases such as multiple sclerosis, and to protect against other infectious diseases, such as the respiratory syncytial virus. “It’s not a new idea: What COVID has shown us is that mRNA vaccines can be an efficacious and safe technology for millions of people,” says Daniel Anderson, a leader in the field of nanotherapeutics and biomaterials at the Massachusetts Institute of Technology and a member of the Koch Institute for Integrative Cancer Research.

Currently, phase one and phase two clinical trials are recruiting participants or are underway to assess the efficacy, tolerability, and safety of therapeutic mRNA vaccines to treat various forms of cancer. These include melanoma, non-small cell lung cancers, gastrointestinal cancer, breast cancer, ovarian cancer, and pancreatic cancer, among others.

“One of the beauties of this technology is it can be used in people agnostic to their cancer type—it doesn’t matter if it’s a breast cancer or lung cancer as long as you can identify its mutations,” says Van Morris, a physician and an assistant professor of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center in Houston who is leading a phase two clinical trial exploring the use of personalized mRNA vaccines for patients who have stage II or stage III colorectal cancer. “One of the exciting things is the adaptability of the technology based on a given cancer and the underlying biology of that cancer.”

Over the course of 27 weeks, Cassidy received nine injections of a personalized mRNA vaccine along with intravenous infusions of an immunotherapy drug called Pembrolizumab. She saw her doctor, Julie E. Bauman, deputy director of the University of Arizona Cancer Center, on a weekly basis at first then every three weeks; she also had regular CT scans. After each injection, Cassidy would spike a fever and feel wiped out—with fatigue and body aches and pains—for 24 hours. “My immune system was really flaring up, which is what we wanted to happen so it could fight the cancer,” she explains.

By the time the treatment concluded in October 2020, Cassidy’s CT scans were clean: There was no evidence of cancer in her body.

A message in a needle
On a basic level, “what we’re trying to do with the mRNA vaccine for cancer is alert the immune system to the tumor so the immune system will attack it—it’s basically biological software,” explains John Cooke, a physician and medical director of the Center for RNA Therapeutics at Houston Methodist. “Vaccines are being developed against cancers where there’s not a very good solution right now or where the cancers are likely to metastasize.”

Some mRNA vaccines for cancer take an off-the-shelf approach: These ready-made vaccines are designed to look for target proteins that appear on the surface of certain cancer tumors. How well they work is a matter of speculation right now, but some experts have concerns. “The question is: What is the target? You always have to have the right thing to target for the vaccine to be effective,” says David Braun, an oncologist at the Dana-Farber Cancer Institute and Harvard Medical School who specializes in immunotherapies. After all, with cancer, there isn’t a universal target the way there is with the coronavirus’s spike protein, and DNA mutations in cancer cells vary from one patient to another.

This is where personalized mRNA cancer vaccines enter the picture—and these may be more promising, experts say. With the personalized approach, a sample of tissue is taken from a patient’s tumor and their DNA is analyzed to identify mutations that distinguish the cancer cells from the normal, healthy cells, explains Bauman, who is also chief of hematology/oncology at the UA College of Medicine-Tucson. Computers compare the two DNA samples to identify the unique mutations in a tumor, then the results are used to design a molecule of mRNA that will go into the vaccine. This is typically done in four-to-eight-weeks—“it’s a technical tour de force to be able to do that,” says Robert A. Seder, chief of the Cellular Immunology Section of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases.

After the mRNA vaccine is injected into the patient, the mRNA tells the patient’s cells to produce proteins that are associated with the specific mutations on their tumor. The tumor protein fragments that are created from the mRNA are then recognized by the patient’s immune system, Morris explains. Basically, the mRNA instructions train the immune system’s T cells—white blood cells that help us fight viruses—to recognize up to 20 mutations in cancer cells and attack only those. The immune system scours the body on a search-and-destroy mission looking for similar tumor cells.

“One of the things cancer does is it can turn on signals to tell the immune system to quiet down so the cancer is not detected,” explains Anderson. “The goal of an mRNA vaccine is to alert and gear up the immune system to go after the characteristic features of tumor cells and attack them.”

“Personalized cancer vaccines wake up specialized killer T cells that recognize abnormal cells and trigger them to kill the cells that are cancer,” Bauman says. “It’s a matter of using our own immune system as the army to eliminate the cancer.”

“This is the epitome of personalized medicine,” says Morris. “It’s a highly personalized, highly specific approach, not a one-size-fits-all treatment.”

Challenges ahead
Despite the enthusiasm and promise for this type of cancer treatment, it is important to remember: “These are early days, and the results are going to be different than the immediate success of the COVID-19 vaccines,” says Seder. For one thing, mRNA cancer vaccines aren’t going to become available at record speed the way the COVID-19 vaccines did under emergency use authorization; the cancer vaccines will require years of testing and clinical trials.

One reason for the differences in the development time for COVID-19 mRNA vaccines versus cancer mRNA vaccines stems from their therapeutic goal. The current mRNA vaccines are intended to prevent COVID-19: They’re designed to protect people from the virus by providing a preview of the coronavirus’s distinctive spike protein, so that if they encounter the virus, their immune system can fight it off. By contrast, cancer mRNA vaccines are therapies: They are given to patients to teach their immune systems to seek and destroy existing tumor cells.

Another challenge with mRNA vaccines has been to figure out how to build a nanoparticle that effectively delivers messenger RNA to where it needs to go. “If it’s [left] unprotected, messenger RNA won’t enter cells, and it will be rapidly degraded when you put it in the body,” explains Anderson. “We can protect it and deliver it inside cells by encapsulating it in a lipid-like nanoparticle.” This way, the nanoparticles can evade the body’s clearance mechanisms and get into the right cells. (Currently, lipid-based nanoparticles are the most common delivery system used in clinical trials for mRNA vaccines to treat cancer.)

Even with an optimal delivery system, however, it’s unlikely that mRNA vaccines will be a panacea for all cancers. But they are another promising tool for the treatment of advanced or incurable cancers. And researchers are exploring whether mRNA vaccines can be combined with other immune-based therapies, such as checkpoint inhibitors (which release a natural brake on the immune system so that T cells can recognize and attack tumors) or adoptive T cell therapy (in which T cells are harvested from a patient’s blood or tumor, stimulated to grow in the lab, then reinfused into a patient to help the body recognize and destroy tumor cells).

At this point, there are few published studies of trials with mRNA cancer vaccines in humans, but there are glimmers of optimism. In a phase one trial that investigated the use of an mRNA vaccine along with an immune checkpoint inhibitor in the treatment of head and neck cancer or colorectal cancer, Bauman and her colleagues found noteworthy differences: In five of the 10 patients with head and neck cancer, the combination therapy shrank the tumors and two patients had no detectable cancer after the treatment; by contrast, the 17 patients with colorectal cancer failed to respond to the combination treatment.

“With colorectal cancer, there isn’t much immune system activity—the cancer cells are better at hiding,” explains Bauman. “In some cases, it may not be enough to show the immune system what the cancer looks like.” The T cells need to reach the cancer and eliminate it. That didn’t happen with the patients who had colorectal cancer.

Hope on the horizon
Meanwhile, some promising findings are emerging from animal studies. In a study in a 2018 issue of the journal Molecular Therapy, researchers constructed an mRNA vaccine to be combined with a monoclonal antibody (a synthetic antibody made in the lab) to enhance the anti-tumor benefits in the treatment of triple negative breast cancer, which is notoriously aggressive and has a high rate of metastasis and a poor prognosis. They found that mice that were treated with the combination therapy had a significantly enhanced anti-tumor immune response compared to those who were given only the vaccine or the monoclonal antibody. And a study in a 2019 issue of the journal ACS Nano found that when mice with lymphoma (cancer of the lymphatic system) were given an mRNA vaccine along with a checkpoint inhibitor drug, they experienced significantly reduced tumor growth and 40 percent of them experienced complete tumor regression.

If mRNA vaccines prove to be effective, physicians and researchers hope that eventually vaccines could be developed to treat certain cancers, prevent recurrences, and possibly even prevent some cancers in those who are genetically predisposed to them. “I think this is going to be another arrow in the quiver for oncologists to give their patients a better chance,” says Cooke. “And if prophylactic cancer vaccines are shown to work, they could make cancer a preventable illness.”

In the meantime, Molly Cassidy is already a firm believer in the power of mRNA vaccines to treat aggressive cancers. These days, she’s feeling great and enjoying life as a stay-at-home mom with her three-year-old son, her husband, and her step-kids. “My doctor won’t say I’m cured, but she’s very happy with where I am,” says Cassidy. “This treatment saved my life, and I’m incredibly grateful to my doctors.”

Some experts say it’s conceivable that we could see an mRNA vaccine for cancer gain approval by the Food and Drug Administration within the next five years. “If we can leverage the ability of the immune system to precisely get rid of foreign invaders like cancer, that would be an amazing day,” says Bauman.

nationalgeographic.co.uk
investorshub.advfn.com

[Esoteric1] $RGBP $$$$ investorshub.advfn.com

Esoteric1 — 11/14/2021 8:21:33 AM

[Esoteric1] $RGPB twitter.com

Esoteric1 — 11/13/2021 6:49:08 PM

[Esoteric1] twitter.com

Esoteric1 — 11/13/2021 4:17:51 PM

[Esoteric1] stocktwits.com stocktwits.com

Esoteric1 — 11/13/2021 4:22:58 AM

[Esoteric1] twitter.com

Esoteric1 — 11/13/2021 3:41:24 AM

[Esoteric1] $RGBP gotta see how this plays out otcmarkets.com

Esoteric1 — 11/12/2021 10:44:22 PM

[Esoteric1] $RGBP this is from feb 2020 which is as luck would have it 1 month before the Pa...

Esoteric1 — 11/11/2021 11:50:42 PM

$RGBP this is from feb 2020 which is as luck would have it 1 month before the Pandemic

NR2F6 functions to repress expression of effector cytokines and acts as an intracellular immune checkpoint

Introduction
The immune system plays a pivotal role in limiting cancer growth (1), and insights into the mechanisms that govern how immune cells sense, interface with, and respond to cancer have led to the development of immunotherapeutic strategies that enhance anti-tumor immunity.

frontiersin.org

Use or lose

[Esoteric1] twitter.com

Esoteric1 — 11/11/2021 11:00:44 AM

[Esoteric1] NR2F6 functions to repress expression of effector cytokines and acts as an intra...

Esoteric1 — 11/11/2021 4:39:12 AM

NR2F6 functions to repress expression of effector cytokines and acts as an intracellular immune checkpoint

Introduction
The immune system plays a pivotal role in limiting cancer growth (1), and insights into the mechanisms that govern how immune cells sense, interface with, and respond to cancer have led to the development of immunotherapeutic strategies that enhance anti-tumor immunity.

frontiersin.org

[Esoteric1] $RGBP anyone know of another penny like this? twitter.com

Esoteric1 — 11/11/2021 3:04:46 AM

[Esoteric1] stocktwits.com

Esoteric1 — 11/10/2021 2:41:19 AM

[Esoteric1] Found it. Message 33298385 Why file an 8k if there’s no chance? Use or lose

Esoteric1 — 11/9/2021 10:29:14 PM

[Esoteric1] $RGBP for the chart people stocktwits.com Lol they called the extra market ma...

Esoteric1 — 11/9/2021 9:02:40 PM

$RGBP for the chart people

stocktwits.com

Lol they called the extra market makers a joint task force

stocktwits.com

stocktwits.com

[Esoteric1] $RGBP look through the sec filings for the poison pill that prevents hostile tak...

Esoteric1 — 11/9/2021 8:20:29 PM

$RGBP look through the sec filings for the poison pill that prevents hostile takeovers.

twitter.com

There is no way to know what might happen

Use or lose

[Esoteric1] $RGBP mobile.twitter.com Use or lose. Who knows

Esoteric1 — 11/9/2021 8:44:59 AM

[Esoteric1] Try googling some of these names and the nr2f6 checkpoint inhibitor investorshu...

Esoteric1 — 11/9/2021 12:34:44 AM

Try googling some of these names and the nr2f6 checkpoint inhibitor

investorshub.advfn.com

When ONPH cash register rings, RGBP cash register rings

Good news is if it’s only a collaboration/joint venture numbers like this are possible since RGBP already achieved them 6-30-2021
increase of approximately 6, 946% is attributable to $1,905,000 of revenue recognized during the quarter ended June 30, 2021 pursuant to a license granted to Oncology Pharma,Inc. Operating Income was $1,833,303 for the quarter ended June 30,2021 whereas Operating Loss was $16,336 for the same quarter ended 2020; an increase primarily attributable to $1,905,000 of revenue recognized during the quarter ended June 30,2021 pursuant to a license granted to Oncology Pharma,Inc

Read under disclosure tab

otcmarkets.com

twitter.com

twitter.com

Use or lose

[Esoteric1] $RGBP food for thought investorshub.advfn.com Use or lose

Esoteric1 — 11/8/2021 8:19:33 AM

[Esoteric1] $RGBP stocktwits.com For the $RGBP chart fans. Dude has 28k followers twitter....

Esoteric1 — 11/8/2021 7:55:01 AM

$RGBP stocktwits.com

For the $RGBP chart fans. Dude has 28k followers

twitter.com

stocktwits.com

[Esoteric1] $RGBP $$ a trip down memory lane. CREDIT:Nothing100percent STOCKTWITS Bulli...

Esoteric1 — 11/8/2021 7:24:16 AM

$RGBP $$ a trip down memory lane.

CREDIT:Nothing100percent STOCKTWITS
Bullish
9/22/21, 07:47 AM
$RGBP
*** NEWBIES ***
**
08/04/20 Ran about 800% in 3 Days
**
12/02/20 Ran over 600% in 1 Day
**
02/01/21 Ran about 400% in 7 Days
**
04/08/21 Ran almost 4,000% in 3 Days
**
08/17/21 Ran about 275% in 9 Days
**
Not trying to time this beast.
**
$RGBP
Up 13,233% YTD
**
Those numbers are AWESOME! I'll be in for the next MASSIVE run.
**
I'm in and HOLDING!
**
GLTA

stocktwits.com

Upcoming catalyst

investorshub.advfn.com

mobile.twitter.com

mobile.twitter.com

Shorts may want to cover or get squeezed

otcshortreport.com

Regular VolumeShort VolumeOct 11Oct 13Oct 15Oct 19Oct 21Oct 25Oct 27Oct 29Nov 02Nov 04Oct 12Oct 14Oct 18Oct 20Oct 22Oct 26Oct 28Nov 01Nov 03Nov 05050,000,000100,000,000150,000,000200,000,000250,000,000300,000,000Highcharts.com

Historical Short Volume Data for RGBP
DateCloseHighLowVolumeShort Volume% of Vol Shorted

Nov 05

213,234,005

102,134,243

47.90

You may as always use or lose this info.

I truly hope all prosper

That is all

[Benny-Rubin] $TSOI has huge news today on a cell they invented, Therapeutic Solutions Interna...

Benny-Rubin — 3/23/2021 10:13:01 AM

$TSOI has huge news today on a cell they invented, Therapeutic Solutions International Creates Hybrid Cell Designed to Educate Immune System to Choke Cancer Blood VesselsNovel Strategy Demonstrates Potent Results in Animal Model of Lung Cancer through Fusing StemVacs-V™ Immunotherapy with In-Vitro Generated Cancer Blood Vessels
ELK CITY, Idaho, March 23, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of a patent with new data on a unique cell created by the Company capable of training the immune system to kill blood vessels feeding cancer, but sparing healthy blood vessels. These data are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production.

"Killing malignant blood vessels is the basis for Avastin, an antibody-based drug which created 7 billion in revenue last year.1 Another company, Batu Biologics, previously demonstrated vaccination against cancer blood vessels is safe and was cleared by the FDA for clinical trials," stated Dr. James Veltmeyer, Chief Medical Officer of the Company. "The approach developed by our Company is completely unique because it merges the potent antigen presenting capabilities of StemVacs-V together with the reproducibility and consistency of iPSC generated tumor-like endothelial cells."

StemVacs-V™ is comprised of "cancer resistant" dendritic cells which are developed from an engineered iPSC cell line. The novel chimeric cell product is generated by fusing StemVacs-V with iPSC derived endothelial cells which are cultured in a manner to make them replicate cancer stem cells. Proof of selective killing of cancer blood vessels was obtained by demonstration of immune response to proteins found only on cancer blood vessels.

"Numerous companies such as Fate Therapeutics, NantKwest, and Century Therapeutics have all achieved significant valuations through pioneering novel uses of iPSC derived immune cells," said Famela Ramos, Vice President of Business Development. "To our knowledge we are the first company to use iPSC derived cells to stimulate naturally occurring immunity to kill what some call the 'Achilles Heel' of cancer."

"Generation of a new cell that didn't previously exist is a significant milestone for our Company. We believe the current animal studies in lung cancer can be extrapolated to other cancers, since no cancer can grow more than 2 millimeters without creating new blood vessels," said Timothy Dixon, President and CEO of the Company and co-inventor of the patent. "By selectively killing cancer blood vessels the problem of mutations is solved since cancer blood vessels are not generated from tumor tissue and they do not mutate. Furthermore, since blood vessels are in direct contact with the blood and immune cells that travel through the blood, it is substantially easier for the immune system to kill malignant vessels as opposed to tumors."

[Benny-Rubin] Hi Gary,thank you for the message.I know EWLL from several years back but never ...

Benny-Rubin — 3/21/2021 12:47:20 AM

Hi Gary,thank you for the message.I know EWLL from several years back but never bought it but now I will put her back on my screen and keep an eye on it. The post you answered on my TSOI posting soared to .17 last month and now has settled in the .10 area. Company is waiting on word from the FDA on their JediCell and maybe we get an answer this week. Their Quadramune is in Phase 2 and StemVacs in Phase 1.

In June 2019 the Company was on their last leg trading 0004 and its just amazing how the CEO got out of the hole. Their Lung Cancer drugs has shown some amazing possitive effects on Covid19 hence the FDA is allowing this Company trials with anywhere from 500 to 1200 to participate

SI used to be a great site for penny stocks and its too bad nobody kept that alive.

[Gary Mohilner] If you're looking for something under $.01, take a look at EWLL. I got in a few...

Gary Mohilner — 3/20/2021 7:25:35 PM

If you're looking for something under $.01, take a look at EWLL. I got in a few months ago at $.0003, at that time it was clear they were hurting for cash and behind on financial. The price has reached over $.002 but they're still in the same status. Nothing official has come from the company, but I like their position, doing therapy on the net, and I believe that they'll either grow, or be bought out for the software they own at least a part of, either way it should be worth more than it is today.

I welcome others thoughts about it.

Gary

[Benny-Rubin] My remedial math skills suck but will say approx 700% gain this week on TSOI. 00...

Benny-Rubin — 6/12/2020 6:39:22 PM

My remedial math skills suck but will say approx 700% gain this week on TSOI. 0033 to High 0189 close 017. Maybe another sub penny pick for next week? What do you think???

[Benny-Rubin] TSOI 0033 looks ok for some upward movement tomorrow.

Benny-Rubin — 6/7/2020 7:25:25 PM

[kerfluffel] ECDC super cheap. Wondering if anyone knows what is happening with Hawkeye they...

kerfluffel — 3/14/2017 9:17:49 PM

ECDC super cheap. Wondering if anyone knows what is happening with Hawkeye they were working on

[Benny-Rubin] Many congrats to you on FROZ!!! EXMT = this chart is out of this world otcmarket...

Benny-Rubin — 3/24/2014 7:02:50 AM

Many congrats to you on FROZ!!! EXMT = this chart is out of this world otcmarkets.com

DSCR pulled back from 006 to 0038 and I might dabble in some. TRTC should have a great day.

Best of luck to you Rock!